Refine
Has Fulltext
- yes (25)
Is part of the Bibliography
- yes (25)
Year of publication
Document Type
- Journal article (24)
- Conference Proceeding (1)
Language
- English (25)
Keywords
- PRRT (6)
- dosimetry (6)
- 53BP1 (3)
- γ-H2AX (3)
- 177Lu (2)
- CXCR4 (2)
- PET/CT (2)
- biodosimetry (2)
- chemokine receptor (2)
- neuroendocrine tumor (2)
- positron emission tomography (2)
- quantitative SPECT/CT (2)
- repair (2)
- 131I (1)
- 133Ba (1)
- 177Lu SPECT/CT imaging (1)
- 177Lu-DOTATATE (1)
- 177Lu-DOTATOC (1)
- 223Ra (1)
- 224Ra (1)
- 3D printing (1)
- 5IA-SPECT (1)
- BSS directive (1)
- Barium-133 (1)
- Biokinetics (1)
- Combination (1)
- DNA Breaks (1)
- DNA damage (1)
- DNA double-strand breaks (1)
- DNA repair (1)
- DOTATOC (1)
- DSB damage (1)
- DSB focus substructure (1)
- Deep learning (1)
- Denoising (1)
- Diagnostic radiopharmaceuticals (1)
- Dosimetry (1)
- EANM dosage card (1)
- EBRT (1)
- Effective dose (1)
- Ga-68 (1)
- JR11 (1)
- Lu-177 (1)
- Lutetium (1)
- MAG3 (1)
- Medizin (1)
- Meningioma (1)
- Monte Carlo (1)
- Neuroendocrine Tumor (1)
- OPS201 (1)
- PET (1)
- PET/MR systems (1)
- PSMA (1)
- Parkinson disease (1)
- Peptide receptor radionuclide therapy (1)
- Positronen-Emissions-Tomografie (1)
- Ra-224 (1)
- Radiotherapy (1)
- Radium (1)
- SPECT (1)
- SPECT/CT (1)
- SSTR (1)
- Single Molecule Localization Microscopy (SMLM) (1)
- [\(^{68}\)Ga]Pentixafor (1)
- \(^{177}\)Lu-OPS201 (1)
- absorbed dose to the blood (1)
- acute myeloid leukemia (1)
- alpha particles (1)
- alpha-emitters (1)
- antagonist (1)
- biokinetics (1)
- biological dosimetry (1)
- biomarkers (1)
- blood (1)
- bone-targeting radiopharmaceuticals (1)
- calibration (1)
- cancer treatment (1)
- chromatin mobility (1)
- cognitive decline (1)
- comparison exercise (1)
- complex DNA damage (1)
- contrast agent (1)
- damage (1)
- dopamine acetylcholine (1)
- dose response (1)
- double-stranded (1)
- epidemiology (1)
- gamma rays (1)
- harmonization of SPECT/CT imaging (1)
- health care (1)
- healthy volunteers (1)
- high LET irradiation (1)
- histone H2AX (1)
- humans (1)
- in vivo formation (1)
- in vivo imaging (1)
- international multicenter comparison exercise (1)
- irradiation (1)
- isotopes (1)
- leukocytes (1)
- lutetium-177 (1)
- lymphoma (1)
- medicine (1)
- molecular radiotherapy (1)
- molecular radiotherapy (MRT) (1)
- multi-centre (1)
- neuroendocrine tumor (NET) (1)
- neuroendocrine tumors (1)
- nicotinic receptors (1)
- nuclear medicine (1)
- nuclear medicine therapy (1)
- optimization (1)
- peptide receptor radionuclide therapy (1)
- phantom (1)
- phosphorylation (1)
- photons (1)
- pig model (1)
- prognostic value (1)
- prostate cancer (1)
- quantitative imaging (1)
- radiation effects (1)
- radiobiology (1)
- radioiodine (1)
- radioiodine therapy (1)
- radionuclide therapy (1)
- radium (1)
- renal scintigraphy (1)
- signal to noise ratio (1)
- solid surrogate source (1)
- standardization of SPECT/CT imaging (1)
- super ultraviolet (1)
- theranostics (1)
- therapeutic target (1)
- thyroid cancer (1)
- thyroid carcinomas (1)
- traceability of SPECT/CT imaging (1)
- α-Particle (1)
- α-emitter (1)
Institute
Sonstige beteiligte Institutionen
EU-Project number / Contract (GA) number
- 701983 (2)
Background
\(^{177}\)Lu is used in peptide receptor radionuclide therapies for the treatment of neuroendocrine tumors. Based on the recent literature, SST2 antagonists are superior to agonists in tumor uptake. The compound OPS201 is the novel somatostatin antagonist showing the highest SST2 affinity. The aim of this study was to measure the in vivo biodistribution and dosimetry of \(^{177}\)Lu-OPS201 in five anesthetized Danish Landrace pigs as an appropriate substitute for humans to quantitatively assess the absorbed doses for future clinical applications.
Results
\(^{177}\)Lu-OPS201 was obtained with a specific activity ranging from 10 to 17 MBq/μg. Prior to administration, the radiochemical purity was measured as s > 99.7 % in all cases. After injection, fast clearance of the compound from the blood stream was observed. Less than 5 % of the injected activity was presented in blood 10 min after injection. A series of SPECT/CT and whole-body scans conducted until 10 days after intravenous injection showed uptake mostly in the liver, spine, and kidneys. There was no visible uptake in the spleen. Blood samples were taken to determine the time-activity curve in the blood. Time-activity curves and time-integrated activity coefficients were calculated for the organs showing visible uptake. Based on these data, the absorbed organ dose coefficients for a 70-kg patient were calculated with OLINDA/EXM. For humans after an injection of 5 GBq \(^{177}\)Lu-OPS201, the highest predicted absorbed doses are obtained for the kidneys (13.7 Gy), the osteogenic cells (3.9 Gy), the urinary bladder wall (1.8 Gy), and the liver (1.0 Gy). No metabolites of 177Lu-OPS201 were found by radio HPLC analysis. None of the absorbed doses calculated will exceed organ toxicity levels.
Conclusions
The \(^{177}\)Lu-OPS201 was well tolerated and caused no abnormal physiological or behavioral signs. In vivo distributions and absorbed doses of pigs are comparable to those observed in other publications. According to the biodistribution data in pigs, presented in this work, the expected radiation exposure in humans will be within the acceptable range.
We investigated in vivo brain nicotinic acetylcholine receptor (nAChR) distribution in cognitively intact subjects with Parkinson's disease (PD) at an early stage of the disease. Fourteen patients and 13 healthy subjects were imaged with single photon emission computed tomography and the radiotracer 5-[(123)I]iodo-3-[2(S)-2-azetidinylmethoxy]pyridine ([(123)I]5IA). Patients were selected according to several criteria, including short duration of motor signs (<7 years) and normal scores at an extensive neuropsychological evaluation. In PD patients, nAChR density was significantly higher in the putamen, the insular cortex and the supplementary motor area and lower in the caudate nucleus, the orbitofrontal cortex, and the middle temporal gyrus. Disease duration positively correlated with nAChR density in the putamen ipsilateral (ρ = 0.56, p < 0.05) but not contralateral (ρ = 0.49, p = 0.07) to the clinically most affected hemibody. We observed, for the first time in vivo, higher nAChR density in brain regions of the motor and limbic basal ganglia circuits of subjects with PD. Our findings support the notion of an up-regulated cholinergic activity at the striatal and possibly cortical level in cognitively intact PD patients at an early stage of disease.
Various single or multi-modality therapeutic options are available to treat pain of bone metastasis in patients with prostate cancer. Different radionuclides that emit β-rays such as 153Samarium and 89Strontium and achieve palliation are commercially available. In contrast to β-emitters, 223Radium as a α-emitter has a short path-length. The advantage of the α-emitter is thus a highly localized biological effect that is caused by radiation induced DNA double-strand breaks and subsequent cell killing and/or limited effectiveness of cellular repair mechanisms. Due to the limited range of the α-particles the bone surface to red bone marrow dose ratio is also lower for 223Radium which is expressed in a lower myelotoxicity. The α emitter 223Radium dichloride is the first radiopharmaceutical that significantly prolongs life in castrate resistant prostate cancer patients with wide-spread bone metastatic disease. In a phase III, randomized, double-blind, placebo-controlled study 921 patients with castration-resistant prostate cancer and bone metastases were randomly assigned. The analysis confirmed the 223Radium survival benefit compared to the placebo (median, 14.9 mo vs 11.3 mo; P < 0.001). In addition, the treatment results in pain palliation and thus, improved quality of life and a delay of skeletal related events. At the same time the toxicity profile of 223Radium was favourable. Since May 2013, 223Radium dichloride (Xofigo®) is approved by the US Food and Drug Administration.
Core tip: The incidence rate of prostate cancer worldwide is high. Ninety percent of patients dying of prostate cancer have bone metastases with varying symptoms which are significantly impairing their quality of life. 223Radium is the first therapeutic that results in a survival benefit for patients with bone metastatic, castrate resistant prostate cancer. 223Radium was also associated with low myelosuppression rates and fewer adverse events.This article provides an overview of the pre-clinical and clinical trials with 223Radium.
Objectives
The aim of this study is to evaluate the quality of I-124 PET images with and without prompt gamma compensation (PGC) by comparing the recovery coefficients (RC), the signal to noise ratios (SNR) and the contrast to F-18 and Ga-68. Furthermore, the influence of the PGC on the quantification and image quality is evaluated.
Methods
For measuring the image quality the NEMA NU2-2001 PET/SPECT-Phantom was used containing 6 spheres with a diameter between 10 mm and 37 mm placed in water with different levels of background activity. Each sphere was filled with the same activity concentration measured by an independently cross-calibrated dose calibrator. The “hot” sources were acquired with a full 3D PET/CT (Biograph mCT®, Siemens Medical USA). Acquisition times were 2 min for F-18 and Ga-68, and 10 min for I-124. For reconstruction an OSEM algorithm was applied. For I-124 the images were reconstructed with and without PGC. For the calculation of the RCs the activity concentrations in each sphere were determined; in addition, the influence of the background correction was studied.
Results
The RCs of Ga-68 are the smallest (79%). I-124 reaches similar RCs (87% with PGC, 84% without PGC) as F-18 (84%). showing that the quantification of I-124 images is similar to F-18 and slightly better than Ga-68. With background activity the contrast of the I-124 PGC images is similar to Ga-68 and F-18 scans. There was lower background activity in the I-124 images without PGC, which probably originates from an overcorrection of the scatter contribution. Consequently, the contrast without PGC was much higher than with PGC. As a consequence PGC should be used for I-124.
Conclusions
For I-124 there is only a slight influence on the quantification depending on the use of the PGC. However, there are considerable differences with respect to I-124 image quality.
Background: External beam radiotherapy (EBRT) is the treatment of choice for irresectable meningioma. Due to the strong expression of somatostatin receptors, peptide receptor radionuclide therapy (PRRT) has been used in advanced cases. We assessed the feasibility and tolerability of a combination of both treatment modalities in advanced symptomatic meningioma. Methods: 10 patients with irresectable meningioma were treated with PRRT (177Lu-DOTA0,Tyr3 octreotate or - DOTA0,Tyr3 octreotide) followed by external beam radiotherapy (EBRT). EBRT performed after PRRT was continued over 5–6 weeks in IMRT technique (median dose: 53.0 Gy). All patients were assessed morphologically and by positron emission tomography (PET) before therapy and were restaged after 3–6 months. Side effects were evaluated according to CTCAE 4.0. Results: Median tumor dose achieved by PRRT was 7.2 Gy. During PRRT and EBRT, no side effects>CTCAE grade 2 were noted. All patients reported stabilization or improvement of tumor-associated symptoms, no morphologic tumor progression was observed in MR-imaging (median follow-up: 13.4 months). The median pre-therapeutic SUVmax in the meningiomas was 14.2 (range: 4.3–68.7). All patients with a second PET after combined PRRT + EBRT showed an increase in SUVmax (median: 37%; range: 15%–46%) to a median value of 23.7 (range: 8.0–119.0; 7 patients) while PET-estimated volume generally decreased to 81 ± 21% of the initial volume. Conclusions: The combination of PRRT and EBRT is feasible and well tolerated. This approach represents an attractive strategy for the treatment of recurring or progressive symptomatic meningioma, which should be further evaluated.